Enlivex Ltd. ENLV
NASDAQ · United States · Health Technology
$0.3873-0.04 (-8.37%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Investing.com -- The FDA has granted Regenerative Medicine Advanced Therapy designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis, Investing.com has learned.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.